Shukla Sath's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Feb 3, 2023
- Accession no.
- 0000899243-23-003945
- Filed
- Feb 3, 2023
- Trade date
- Feb 1-2, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $17.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SathCIK 0001782817 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Common Stock | AGrant or awardAcquired | +265,957 | $0.00 | $0 | 322,021 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −9,504 | $1.83 | −$17,392.32 | 312,517 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.